Previous Close | 93.84 |
Open | 93.50 |
Bid | 92.47 x 100 |
Ask | 92.59 x 200 |
Day's Range | 92.45 - 94.64 |
52 Week Range | 73.68 - 99.56 |
Volume | |
Avg. Volume | 2,382,695 |
Market Cap | 17.624B |
Beta (5Y Monthly) | 0.32 |
PE Ratio (TTM) | 70.13 |
EPS (TTM) | 1.32 |
Earnings Date | Oct 30, 2024 - Nov 04, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 109.39 |
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced the appointments of Greg Friberg, M.D., as Executive Vice President, Chief Research & Development Officer, succeeding Hank Fuchs, M.D., and James Sabry, M.D., Ph.D., as Executive Vice President, Chief Business Officer.
Greg Friberg and James Sabry will take over, respectively, as heads of R&D and business development, less than a year after BioMarin named a new CEO.
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) will host an Investor Day with financial analysts and institutional investors on Wednesday, September 4, 2024, in New York City from 10:30 am to 1:00 pm Eastern Time. The event will feature presentations from members of the executive management team and will highlight BioMarin's pipeline, strategic plans, growth opportunities and long-term financial outlook.